Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This review discusses the unmet supportive care needs of men and women experiencing chemotherapy-induced alopecia and reports no new results, urging healthcare providers to tailor interventions to individual patient needs.

In this systematic meta-synthesis, the researchers observed substantial variation in how individuals with alopecia manage identity and appearance changes, highlighting difficulties with acceptance, social influences, and unmet treatment needs, thus emphasizing personalized support through non-pharmacological interventions.

In this case report, researchers describe a 13-year-old phenotypic female with 46,XY karyotype, previously misdiagnosed with androgen insensitivity syndrome, who was later identified to have 17-beta-hydroxysteroid dehydrogenase type 3 deficiency, underscoring the importance of genetic and hormonal tests for accurate diagnosis of sex development disorders.

This study elucidated the multi-component and multi-target mechanisms by which TR and Am may provide therapeutic benefits for treating androgenetic alopecia.

In this study, human dermal fibroblasts were identified as natural host cells that support productive Merkel cell polyomavirus infection, and the MEK antagonist trametinib was introduced as an effective inhibitor to control the virus.